ITRM20050447A1 - Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson. - Google Patents

Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.

Info

Publication number
ITRM20050447A1
ITRM20050447A1 IT000447A ITRM20050447A ITRM20050447A1 IT RM20050447 A1 ITRM20050447 A1 IT RM20050447A1 IT 000447 A IT000447 A IT 000447A IT RM20050447 A ITRM20050447 A IT RM20050447A IT RM20050447 A1 ITRM20050447 A1 IT RM20050447A1
Authority
IT
Italy
Prior art keywords
disease
parkinson
alzheimer
growth factor
nervous system
Prior art date
Application number
IT000447A
Other languages
English (en)
Inventor
Stefano Bonini
Alessandro Lambiase
Original Assignee
Anabasis S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anabasis S R L filed Critical Anabasis S R L
Priority to IT000447A priority Critical patent/ITRM20050447A1/it
Priority to EP06780613A priority patent/EP1948217B1/en
Priority to PCT/IT2006/000620 priority patent/WO2007020672A2/en
Priority to ES06780613T priority patent/ES2376992T3/es
Priority to RU2008110505/15A priority patent/RU2429007C2/ru
Priority to AT06780613T priority patent/ATE539763T1/de
Priority to CA002619721A priority patent/CA2619721A1/en
Priority to US12/064,172 priority patent/US20090118177A1/en
Priority to DK06780613.3T priority patent/DK1948217T3/da
Priority to JP2008526617A priority patent/JP2009504724A/ja
Publication of ITRM20050447A1 publication Critical patent/ITRM20050447A1/it
Priority to IL189605A priority patent/IL189605A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
IT000447A 2005-08-19 2005-08-19 Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson. ITRM20050447A1 (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IT000447A ITRM20050447A1 (it) 2005-08-19 2005-08-19 Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
AT06780613T ATE539763T1 (de) 2005-08-19 2006-08-11 Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit
PCT/IT2006/000620 WO2007020672A2 (en) 2005-08-19 2006-08-11 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
ES06780613T ES2376992T3 (es) 2005-08-19 2006-08-11 Uso de factor de crecimiento nervioso en gotas oftálmicas para terapia de patologías del sistema nervioso central, tales como enfermedad de Alzheimer y enfermedad de Parkinson
RU2008110505/15A RU2429007C2 (ru) 2005-08-19 2006-08-11 Применение фактора роста нервов в глазных каплях для лечения патологий центральной нервной системы, таких как болезнь альцгеймера и паркинсона
EP06780613A EP1948217B1 (en) 2005-08-19 2006-08-11 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
CA002619721A CA2619721A1 (en) 2005-08-19 2006-08-11 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
US12/064,172 US20090118177A1 (en) 2005-08-19 2006-08-11 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
DK06780613.3T DK1948217T3 (da) 2005-08-19 2006-08-11 Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom
JP2008526617A JP2009504724A (ja) 2005-08-19 2006-08-11 アルツハイマー病又はパーキンソン病のような中枢神経系の病態の治療のための、点眼液における神経成長因子の使用
IL189605A IL189605A (en) 2005-08-19 2008-02-19 Use of ngf for the preparation of eye drops for the treatment of pathologies of the central nervous system, such as Alzheimer's and Parkinson's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000447A ITRM20050447A1 (it) 2005-08-19 2005-08-19 Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.

Publications (1)

Publication Number Publication Date
ITRM20050447A1 true ITRM20050447A1 (it) 2007-02-20

Family

ID=37667295

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000447A ITRM20050447A1 (it) 2005-08-19 2005-08-19 Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.

Country Status (11)

Country Link
US (1) US20090118177A1 (it)
EP (1) EP1948217B1 (it)
JP (1) JP2009504724A (it)
AT (1) ATE539763T1 (it)
CA (1) CA2619721A1 (it)
DK (1) DK1948217T3 (it)
ES (1) ES2376992T3 (it)
IL (1) IL189605A (it)
IT (1) ITRM20050447A1 (it)
RU (1) RU2429007C2 (it)
WO (1) WO2007020672A2 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2173344B1 (en) * 2007-06-29 2016-04-06 Clarencew Pty Ltd. Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
CN101972224B (zh) * 2010-09-13 2012-01-04 舒泰神（北京）生物制药股份有限公司 一种眼用原位凝胶
IT202000032423A1 (it) 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959319A (en) * 1985-08-01 1990-09-25 Skelnik Debra L Process of corneal enhancement
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US6063757A (en) * 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
IT1283911B1 (it) * 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
KR100514277B1 (ko) * 1996-09-13 2005-09-13 유겐가이샤 사이센딴이가꾸겡꾸쇼 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
AU8559398A (en) * 1998-08-05 2000-02-28 Advanced Medicine Research Institute Remedies for cerebral central lesions with the use of neurotrophic factors
AU2173400A (en) * 1998-12-09 2000-06-26 Chiron Corporation Method for administering agents to the central nervous system
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US20020009498A1 (en) * 1999-11-05 2002-01-24 Guy L. Clifton Methods and compositions for treatment of traumatic brain injury
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing

Also Published As

Publication number Publication date
WO2007020672A3 (en) 2007-05-31
JP2009504724A (ja) 2009-02-05
US20090118177A1 (en) 2009-05-07
RU2008110505A (ru) 2009-09-27
CA2619721A1 (en) 2007-02-22
WO2007020672A2 (en) 2007-02-22
EP1948217A2 (en) 2008-07-30
RU2429007C2 (ru) 2011-09-20
EP1948217B1 (en) 2012-01-04
ATE539763T1 (de) 2012-01-15
IL189605A (en) 2013-10-31
IL189605A0 (en) 2008-06-05
DK1948217T3 (da) 2012-02-20
ES2376992T3 (es) 2012-03-21

Similar Documents

Publication Publication Date Title
Peng et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model
Fisher et al. AF150 (S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer’s disease
Hu et al. Osthole reverses beta-amyloid peptide cytotoxicity on neural cells by enhancing cyclic AMP response element-binding protein phosphorylation
Zheng et al. Protective effects of flavonoid extract from Apocynum venetum leaves against corticosterone-induced neurotoxicity in PC12 cells
WO2012006419A3 (en) Pro-neurogenic compounds
MX2022009528A (es) Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
CN103156867B (zh) 预防或治疗淀粉样β肽相关疾病或状况的医药组合物
ITRM20050447A1 (it) Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
Dwivedi et al. Physiology and therapeutic potential of SK, H, and M medium afterhyperpolarization ion channels
WO2013061279A4 (en) Uses of indole-ketones or indolidones as neuro-protective drugs
Muresanu Neuromodulation with pleiotropic and multimodal drugs–future approaches to treatment of neurological disorders
JP2009501208A5 (it)
BR112015000313A2 (pt) piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona
WO2014068171A1 (en) N-substituted 4-aminophenols and corresponding quinone imines
Testa et al. Unusual association of sporadic olivopontocerebellar atrophy and motor neuron disease
IPEK Experimental Parkinson’s disease models
WO2008005577A2 (en) Compositions of polyphenols and methods of use
JP2009504724A5 (it)
JP2009532369A5 (it)
Shi et al. Glycyrrhizic acid promotes sciatic nerves recovery in type 1 diabetic rats and protects Schwann cells from high glucose-induced cytotoxicity
Simoni et al. Neurocognitive profile of patients with continuous flow left ventricular assist device
Wang et al. Reducing neuroinflammation in psychiatric disorders: Novel target of phosphodiesterase 4 (PDE4) and developing of the PDE4 inhibitors
Schneider et al. Hormones and temporal components of speech: sex differences and effects of menstrual cyclicity on speech SP Whiteside, A. Hanson, PE Cowell (UK) 44 Plasma b-amyloid (Ab) 40 concentration, lipid status and age in humans CCT Smith, DJ Betteridge (UK) 48 Brain potentials and self-paced random number generation in humans
BR112015020179A2 (pt) piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-onas